Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CLOZAPINE TREATMENT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 94 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Reitzle, K; Warnke, A; Wewetzer, C; Muller, H
      Agranulocytosis in a schizophrenic child receiving clozapine therapy - clinical picture and therapy. a case report

      ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE
    2. Emsley, R; Oosthuizen, P; Niehaus, D; Stein, D
      Anxiety symptoms in schizophrenia: the need for heightened clinician awareness

      PRIMARY CARE PSYCHIATRY
    3. Russell, JM; Mackell, JA
      Bodyweight gain associated with atypical antipsychotics - Epidemiology andtherapeutic implications

      CNS DRUGS
    4. Hirose, S; Ashby, CR; Mills, MJ
      Effectiveness of ECT combined with risperidone against aggression in schizophrenia

      JOURNAL OF ECT
    5. Liebzeit, KA; Markowitz, JS; Caley, CF
      New onset diabetes and atypical antipsychotics

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    6. Scheepers, FE; Wied, CCG; Westenberg, HGM; Kahn, RS
      The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients

      NEUROPSYCHOPHARMACOLOGY
    7. Scheepers, FE; de Wied, CCG; Kahn, RS
      The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    8. Bouchard, RH; Demers, MF; Simoneau, I; Almeras, N; Villeneuve, J; Mottard, JP; Cadrin, C; Lemieux, I; Despres, JP
      Atypical antipsychotics and cardiovascular risk in schizophrenic patients

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    9. Mir, S; Taylor, D
      Atypical antipsychotics and hyperglycaemia

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    10. Melkersson, KI; Hulting, AL; Brismar, KE
      Elevated levels of insulin, leptin, and blood lipids in olanzapine-treatedpatients with schizophrenia or related psychoses (Reprinted)

      JOURNAL OF CLINICAL PSYCHIATRY
    11. Lindenmayer, JP; Nathan, AM; Smith, RC
      Hyperglycemia associated with the use of atypical antipsychotics

      JOURNAL OF CLINICAL PSYCHIATRY
    12. Remschmidt, H; Hennighausen, K; Clement, HW; Heiser, P; Schulz, E
      The use of atypical neuroleptic drugs in child and adolescent psychiatry

      ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE
    13. Tohen, M; Jacobs, TG; Feldman, PD
      Onset of action of antipsychotics in the treatment of mania

      BIPOLAR DISORDERS
    14. Hawkins, KA
      Novel antipsychotics and the neuropsychological deficiencies of schizophrenia

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    15. Dunayevich, E; McElroy, SL
      Atypical antipsychotics in the treatment of bipolar disorder - Pharmacological and clinical effects

      CNS DRUGS
    16. Lieberman, JA; Golden, R; Stroup, S; McEvoy, J
      Drugs of the psychopharmacological revolution in clinical psychiatry

      PSYCHIATRIC SERVICES
    17. Remschmidt, H; Hennighausen, K; Clement, HW; Heiser, P; Schulz, E
      Atypical neuroleptics in child and adolescent psychiatry

      EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
    18. Wirshing, DA; Erhart, SM; Pierre, JM; Boyd, JA
      Nonextrapyramidal side effects of novel antipsychotics

      CURRENT OPINION IN PSYCHIATRY
    19. Lykouras, L; Zervas, IM; Gournellis, R; Malliori, M; Rabavilas, A
      Olanzapine and obsessive-compulsive symptoms

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    20. Carpenter, WT; Conley, R; Kirkpatrick, B
      On schizophrenia and new generation drugs

      NEUROPSYCHOPHARMACOLOGY
    21. Friedman, JH; Factor, SA
      Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

      MOVEMENT DISORDERS
    22. Rivas-Vazquez, RA; Blais, MA; Rey, GJ; Rivas-Vazquez, AA
      Atypical antipsychotic medications: Pharmacological profiles and psychological implications

      PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
    23. Fenton, WS
      Depression, suicide, and suicide prevention in schizophrenia

      SUICIDE AND LIFE-THREATENING BEHAVIOR
    24. Naber, D
      Long-term phase of schizophrenia: impact of atypical agents

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    25. Raja, M; Azzoni, A
      Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study

      GENERAL HOSPITAL PSYCHIATRY
    26. Melkersson, KI; Hulting, AL; Brismar, KE
      Elevated levels of insulin, leptin, and blood lipids in olanzapine-treatedpatients with schizophrenia or related psychoses

      JOURNAL OF CLINICAL PSYCHIATRY
    27. Buscema, CA; Abbasi, QA; Barry, DJ; Lauve, TH
      An algorithm for the treatment of schizophrenia in the correctional setting: The Forensic Algorithm Project

      JOURNAL OF CLINICAL PSYCHIATRY
    28. Keck, PE; Strakowski, SM; McElroy, SL
      The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia

      JOURNAL OF CLINICAL PSYCHIATRY
    29. Citrome, L; Volavka, J
      Management of violence in schizophrenia

      PSYCHIATRIC ANNALS
    30. Gispen-de Wied, CC
      Stress in schizophrenia: an integrative view

      EUROPEAN JOURNAL OF PHARMACOLOGY
    31. Taylor, DM; McAskill, R
      Atypical antipsychotics and weight gain - a systematic review

      ACTA PSYCHIATRICA SCANDINAVICA
    32. Pillmann, F; Schlote, K; Broich, K; Marneros, A
      Electroencephalogram alterations during treatment with olanzapine

      PSYCHOPHARMACOLOGY
    33. Remington, G; Chong, SA
      Conventional versus novel antipsychotics: changing concepts and clinical implications

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    34. Tibbo, P; Warneke, L
      Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologicoverlap

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    35. Fernandez, HH; Friedman, JH
      The role of atypical antipsychotics in the treatment of movement disorders

      CNS DRUGS
    36. Pinals, DA; Buckley, PF
      Novel antipsychotic agents and their implications for forensic psychiatry

      JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
    37. Malone, RP; Sheikh, R; Zito, JM
      Novel antipsychotic medications in the treatment of children and adolescents

      PSYCHIATRIC SERVICES
    38. Frankenburg, FR
      Choices in antipsychotic therapy in schizophrenia

      HARVARD REVIEW OF PSYCHIATRY
    39. Prior, TI; Chue, PS; Tibbo, P; Baker, GB
      Drug metabolism and atypical antipsychotics

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    40. Volavka, J; Citrome, L
      Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns

      SCHIZOPHRENIA RESEARCH
    41. Blin, O
      A comparative review of new antipsychotics

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    42. Dawkins, K; Lieberman, JA; Lebowitz, BD; Hsiao, JK
      Antipsychotics: Past and future - National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998

      SCHIZOPHRENIA BULLETIN
    43. Battaglia, J; Wolff, TK; Wagner-Johnson, DS; Rush, AJ; Carmody, TJ; Basco, MR
      Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    44. Semba, J; Sakai, MW; Suhara, T; Akanuma, N
      Differential effects of acute and chronic treatment with typical and atypical neuroleptics on c-fos mRNA expression in rat forebrain regions using non-radioactive in situ hybridization

      NEUROCHEMISTRY INTERNATIONAL
    45. Soutullo, CA; Sorter, MT; Foster, KD; McElroy, SL; Keck, PE
      Olanzapine in the treatment of adolescent acute mania: a report of seven cases

      JOURNAL OF AFFECTIVE DISORDERS
    46. Buckley, PF
      New antipsychotic agents: Emerging clinical profiles

      JOURNAL OF CLINICAL PSYCHIATRY
    47. Haack, M; Hinze-Selch, D; Fenzel, T; Kraus, T; Kuhn, M; Schuld, A; Pollmacher, T
      Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis

      JOURNAL OF PSYCHIATRIC RESEARCH
    48. Kane, JM
      Pharmacologic treatment of schizophrenia

      BIOLOGICAL PSYCHIATRY
    49. Breier, A; Hamilton, SH
      Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

      BIOLOGICAL PSYCHIATRY
    50. SUZUKI M; SUN YJ; MURATA M; KURACHI M
      WIDESPREAD EXPRESSION OF FOS PROTEIN-INDUCED BY ACUTE HALOPERIDOL ADMINISTRATION IN THE RAT-BRAIN

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    51. POTENZA MN; MCDOUGLE CJ
      POTENTIAL OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF NONPSYCHOTICDISORDERS

      CNS DRUGS
    52. BUCKLEY PF
      TREATMENT OF SCHIZOPHRENIA - LETS TALK DOLLARS AND SENSE

      American journal of managed care
    53. GOFF DC; EVINS AE
      NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - NEUROBIOLOGICAL MODELS AND TREATMENT RESPONSE

      Harvard review of psychiatry
    54. BUCKLEY PF
      NOVEL ANTIPSYCHOTICS AND PATIENT-CARE IN STATE HOSPITALS

      The Annals of pharmacotherapy
    55. HOWARD R
      COGNITIVE IMPAIRMENT IN LATE-LIFE SCHIZOPHRENIA - A SUITABLE CASE FORTREATMENT

      International journal of geriatric psychiatry
    56. KELLY PH
      DEFECTIVE INHIBITION OF DREAM EVENT MEMORY FORMATION - A HYPOTHESIZEDMECHANISM IN THE ONSET AND PROGRESSION OF SYMPTOMS OF SCHIZOPHRENIA

      Brain research bulletin
    57. MARTIN P; WATERS N; SCHMIDT CJ; CARLSSON A; CARLSSON ML
      RODENT DATA AND GENERAL HYPOTHESIS - ANTIPSYCHOTIC ACTION EXERTED THROUGH 5-HT2A RECEPTOR ANTAGONISM IS DEPENDENT ON INCREASED SEROTONERGICTONE

      Journal of neural transmission
    58. BARNES TRE; MCPHILLIPS MA
      NOVEL ANTIPSYCHOTICS, EXTRAPYRAMIDAL SIDE-EFFECTS AND TARDIVE-DYSKINESIA

      International clinical psychopharmacology
    59. ZITO JM
      PHARMACOECONOMICS OF THE NEW ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA

      The Psychiatric clinics of North America
    60. Toren, P; Laor, N; Weizman, A
      Use of atypical neuroleptics in child and adolescent psychiatry

      JOURNAL OF CLINICAL PSYCHIATRY
    61. Kinon, BJ
      The routine use of atypical antipsychotic agents: Maintenance treatment

      JOURNAL OF CLINICAL PSYCHIATRY
    62. TENEICK AP; NAKAMURA H; REED MD
      DRUG-DRUG INTERACTIONS IN PEDIATRIC PSYCHOPHARMACOLOGY

      The Pediatric clinics of North America
    63. DEQUARDO JR; TANDON R
      DO ATYPICAL ANTIPSYCHOTIC MEDICATIONS FAVORABLY ALTER THE LONG-TERM COURSE OF SCHIZOPHRENIA

      Journal of Psychiatric Research
    64. THOMAS CS; LEWIS S
      WHICH ATYPICAL ANTIPSYCHOTIC

      British Journal of Psychiatry
    65. FREEMAN MP; STOLL AL
      MOOD STABILIZER COMBINATIONS - A REVIEW OF SAFETY AND EFFICACY

      The American journal of psychiatry
    66. AWAD AG; VORUGANTI LNP; HESLEGRAVE RJ
      MEASURING QUALITY-OF-LIFE IN PATIENTS WITH SCHIZOPHRENIA

      PharmacoEconomics
    67. BUCKLEY PF; IBRAHIM ZY; SINGER B; ORR B; DONENWIRTH K; BRAR PS
      AGGRESSION AND SCHIZOPHRENIA - EFFICACY OF RISPERIDONE

      Journal of the American Academy of Psychiatry and the Law
    68. DUCKWORTH K; NAIR V; PATEL JK; GOLDFINGER SM
      LOST TIME, FOUND HOPE AND SORROW - THE SEARCH FOR SELF, CONNECTION, AND PURPOSE DURING AWAKENINGS ON THE NEW ANTIPSYCHOTICS

      Harvard review of psychiatry
    69. BORISON RL
      RECENT ADVANCES IN THE PHARMACOTHERAPY OF SCHIZOPHRENIA

      Harvard review of psychiatry
    70. KANDO JC; SHEPSKI JC; SATTERLEE W; PATEL JK; REAMS SG; GREEN AI
      OLANZAPINE - A NEW ANTIPSYCHOTIC AGENT WITH EFFICACY IN THE MANAGEMENT OF SCHIZOPHRENIA

      The Annals of pharmacotherapy
    71. VISALLI H
      DEVELOPING A BEST PRACTICE MODEL FOR CARE OF PATIENTS WITH POLYDIPSIA

      Journal of nursing care quality
    72. BALLUS C
      EFFECTS OF ANTIPSYCHOTICS ON THE CLINICAL AND PSYCHOSOCIAL BEHAVIOR OF PATIENTS WITH SCHIZOPHRENIA

      Schizophrenia research
    73. LUBLIN H
      TREATMENT-RESISTANT SCHIZOPHRENIA

      Nordic journal of psychiatry
    74. CONLEY RR; BUCHANAN RW
      EVALUATION OF TREATMENT-RESISTANT SCHIZOPHRENIA

      Schizophrenia bulletin
    75. THEODOROPOULOU S; PAPPA H; LYKOURAS L; PAPAGEORGIOU G; PAPASTERIADES C; SAKALIS G
      HUMAN-LEUKOCYTE ANTIGEN SYSTEM IN CLOZAPINE-INDUCED AGRANULOCYTOSIS

      Neuropsychobiology
    76. GOODMAN M; HULL JW; TERKELSEN KG; SMITH TE; ANTHONY D
      FACTOR STRUCTURE OF QUALITY-OF-LIFE - THE LEHMAN INTERVIEW

      Evaluation and program planning
    77. LIPSKA BK; WEINBERGER DR
      NOVEL RESEARCH STRATEGIES IN THE PHARMACOLOGY OF SCHIZOPHRENIA

      Medicamentos de actualidad
    78. NEWTON RA; ELLIOTT JM
      MIANSERIN-INDUCED DOWN-REGULATION OF HUMAN 5-HYDROXYTRYPTAMINE(2A) AND 5-HYDROXYTRYPTAMINE(2C) RECEPTORS STABLY EXPRESSED IN THE HUMAN NEUROBLASTOMA CELL-LINE SH-SY5Y

      Journal of neurochemistry
    79. LINDENMAYER JP; ADITYANJEE; VITALHERNE M; BARK N; GROCHOWSKI S; MOYNIHAN N
      HETEROGENEITY OF SEROTONERGIC RESPONSE IN TREATMENT-REFRACTORY SCHIZOPHRENIA-PATIENTS

      Biological psychiatry
    80. TOLLEFSON GD; SANGER TM
      NEGATIVE SYMPTOMS - A PATH ANALYTIC APPROACH TO A DOUBLE-BLIND, PLACEBO-CONTROLLED AND HALOPERIDOL-CONTROLLED CLINICAL-TRIAL WITH OLANZAPINE

      The American journal of psychiatry
    81. PATEL JK; GREEN AI; KALINOWSKI A; TSUANG MT
      EVALUATION OF A COMPLEX CASE - THE VALUE OF A DRUG WASHOUT PERIOD

      The American journal of psychiatry
    82. STIMMEL GL; DOPHEIDE JA
      PSYCHOTROPIC DRUG-INDUCED REDUCTIONS IN SEIZURE THRESHOLD - INCIDENCEAND CONSEQUENCES

      CNS DRUGS
    83. FRANKENBURG FR; HEGARTY JD
      COST CONSIDERATIONS IN THE TREATMENT OF SCHIZOPHRENIA

      CNS DRUGS
    84. MERCHANT KM; FIGUR LM; EVANS DL
      INDUCTION OF C-FOS MESSENGER-RNA IN RAT MEDIAL PREFRONTAL CORTEX BY ANTIPSYCHOTIC-DRUGS - ROLE OF DOPAMINE D2 AND D3 RECEPTORS

      Cerebral cortex
    85. CARPENTER WT
      MAINTENANCE THERAPY OF PERSONS WITH SCHIZOPHRENIA

      The Journal of clinical psychiatry
    86. WEIDEN P; AQUILA R; STANDARD J
      ATYPICAL ANTIPSYCHOTIC-DRUGS AND LONG-TERM OUTCOME IN SCHIZOPHRENIA

      The Journal of clinical psychiatry
    87. HURLEY MJ; STUBBS CM; JENNER P; MARSDEN CD
      DOPAMINE D-3 RECEPTORS ARE NOT INVOLVED IN THE INDUCTION OF C-FOS MESSENGER-RNA BY NEUROLEPTIC DRUGS - COMPARISON OF THE DOPAMINE D-3 RECEPTOR ANTAGONIST GR103691 WITH TYPICAL AND ATYPICAL NEUROLEPTICS

      European journal of pharmacology
    88. KUPERBERG GR
      ADVANCES IN THE TREATMENT OF SCHIZOPHRENIA

      British journal of clinical practice
    89. KINON BJ; LIEBERMAN JA
      MECHANISMS OF ACTION OF ATYPICAL ANTIPSYCHOTIC-DRUGS - A CRITICAL ANALYSIS

      Psychopharmacology
    90. BROGMUS KE; LESCH A
      ANTIDEPRESSANT-NEUROLEPTIC-INDUCED MYOCLO NUS

      Psychiatrische Praxis
    91. ZITO JM; PROVENZANO G
      PHARMACEUTICAL DECISION-MAKING - PHARMACOEPIDEMIOLOGY OR PHARMACOECONOMICS - WHOS IN THE DRIVERS SEAT

      Psychopharmacology bulletin
    92. DOSE M
      APPROVAL OF CLOZAPINE TREATMENT BY GUARDI ANSHIP-COURT ACCORDING TO SECTION-1904 GERMAN-CIVIL-CODE (BGB)

      Nervenarzt
    93. MELTZER HY
      NEW DRUGS FOR THE TREATMENT OF SCHIZOPHRENIA

      The Psychiatric clinics of North America
    94. PARSA MA; SIMON M; DUBROW C; RAMIREZ LF; MELTZER HY
      PSYCHIATRIC MANIFESTATIONS OF OLIVO-PONTO-CEREBELLAR ATROPHY AND TREATMENT WITH CLOZAPINE

      International journal of psychiatry in medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/12/19 alle ore 01:38:02